Inhibitor Therapeutics, Inc. (INTI) Operating income 2016–2025
Inhibitor Therapeutics, Inc. (INTI) annual operating income history from SEC filings — each fiscal year as reported.
-$3.4MFY2025 · since FY2016: -$7.0M → -$3.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.4M | +6.3% |
| FY2024 | -$3.7M | -7.4% |
| FY2023 | -$3.4M | -417.5% |
| FY2022 | -$657,926 | -102.2% |
| FY2021 | -$325,395 | +69.3% |
| FY2020 | -$1.1M | +61.5% |
| FY2019 | -$2.7M | +39.8% |
| FY2018 | -$4.6M | +10.8% |
| FY2017 | -$5.1M | +27.1% |
| FY2016 | -$7.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More INTI financial trends
INTI RevenueINTI Net incomeINTI Net marginINTI Gross profitINTI Gross marginINTI Operating marginINTI Operating cash flowINTI Free cash flowINTI Capital expendituresINTI Return on equityINTI Stock buybacksINTI Dividends paidINTI Total assetsINTI Total liabilitiesINTI Shareholders’ equityINTI overview →